Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate

Figure 8

Percentage of patients with clinically significant reduction of the volume of the fibroids of ≥ 25% (FAS1) [9].